Header Logo

Connection

MICHAEL LEWIS to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications MICHAEL LEWIS has written about Drug Resistance, Neoplasm.
MICHAEL LEWIS
Connection Strength
1.121
Drug Resistance, Neoplasm
  1. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694.
    View in: PubMed
    Score: 0.202
  2. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
    View in: PubMed
    Score: 0.142
  3. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Res. 2019 08 15; 79(16):4258-4270.
    View in: PubMed
    Score: 0.120
  4. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun. 2018 09 19; 9(1):3815.
    View in: PubMed
    Score: 0.114
  5. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.075
  6. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21.
    View in: PubMed
    Score: 0.070
  7. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.
    View in: PubMed
    Score: 0.065
  8. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.060
  9. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.
    View in: PubMed
    Score: 0.056
  10. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
    View in: PubMed
    Score: 0.056
  11. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
    View in: PubMed
    Score: 0.045
  12. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
    View in: PubMed
    Score: 0.033
  13. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer. Proc Natl Acad Sci U S A. 2020 05 05; 117(18):9912-9921.
    View in: PubMed
    Score: 0.032
  14. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Mol Cancer Res. 2019 10; 17(10):2063-2076.
    View in: PubMed
    Score: 0.030
  15. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015 Feb 10; 17:17.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.